2011 Fiscal Year Final Research Report
Study on a new combination chemotherapy for head and neck squamous cell carcinomas
| Project/Area Number |
21390543
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Kanagawa Dental College |
|---|
Principal Investigator |
KUBOTA Eiro 神奈川歯科大学, 歯学部, 教授 (50170030)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MAEHATA Yojiro 神奈川歯科大学, 歯学部, 講師 (80410009)
SUZUKI Kenji 神奈川歯科大学, 歯学部, 歯学部 (80350536)
OZAWA Shigeyuki 神奈川歯科大学, 歯学部, 助教 (40434394)
KONDO Tadanori 神奈川歯科大学, 附属病院, 医員 (00587727)
KATO Yasumasa 神奈川歯科大学, 歯学部, 准教授 (50214408)
ITO Shin 神奈川歯科大学, 歯学部, 特別研究員 (00460139)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | ケモカイン / BRAK / メチル化 / EGFR阻害剤 |
|---|
| Research Abstract |
BRAK/CXCL14 is a chemokine that is expressed in normal tissues, and is important for maintaining homeostasis. BRAK has many functions such as inhibition of angiogenesis and chemotaxis of monocytes as well as macrophaghes. BRAK is absent from or expressed at very low levels in head and neck squamous cell carcinoma(HNSCC), and this is closely correlated with tumorigenesis and progression of HNSCC. Forced expression of BRAK chemokine by the gene transfection into HNSCC or BRAK transgenic mice reduced the tumorigenicity of the cells in xenografts, and BRAK was considered to be a target molecule for the cancer treatment. In the present study, we elucidated that low expression of BRAK in HNSCC was due to mutation of BRAK promotor region by methylation. The low expression level of BRAK in HNSCC is restored by treatment of the cells with anti-methylation drug. HNSCC overexpressed BRAK by EGF receptor antagonist(gefitinib) and anti-methylation drug gave rise to susceptible to tumor regression. The anti-tumor effect using gefitinib and anti-cancer drugs is thus feasible for combination chemotherapy in HNSCC.
|
-
-
-
-
-
-
-
[Journal Article] Restoration of BRAK/CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma2009
Author(s)
Ozawa S, Kato Y, Ito S, Komori R, Shiiki N, Tsukinoki K, Ozono S, Maehata Y, Taguchi T, Imagawa-Ishiguro Y, Tsukuda M, Kubota E, Hata R
-
Journal Title
Cancer Science
Volume: 100
Pages: 2202-2209
DOI
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] A New Mechanism of tumor suppression by gefitinib in HNSCC2009
Author(s)
Ozawa S, Kato Y, Ito S, Komori R, Shiiki N, Tsukinoki K, Ozono S, Maehata Y, Taguchi T, Imagawa-Ishiguro Y, Kubota E, Hata R
Organizer
87th General Session & Exhibition of the IADR. 38th Annual Meeting of the AADR. 33rd Annual Meeting of the CADR
Place of Presentation
Miami Beach Convention Center, Miami, Florida
Year and Date
20090000
-
-
-
[Presentation] Chemokine BRAK stimulates apoptosis elicited by gefitinib in oral squamous cell carcinoma2009
Author(s)
Ito S, Ozawa S, Shiiki N, Tsukinoki K, Kubota E, Kato Y, Taguchi T, Imagawa-Ishiguro Y, Tsukuda M, Hata R
Organizer
Yokosuka Science Festa
Place of Presentation
Shonan Village Center, Hayama
Year and Date
20090000
-
[Presentation] Expression of BRAK/CXCL14 is associated with antitumor efficacy of gefitinib in head and neck squamous cell carcinoma2009
Author(s)
Ozawa S, Kato Y, Ito S, Komori R, Suzuki K, Tsukinoki K, Maehata Y, Taguchi T, Imagawa-Ishiguro Y, Tsukuda M, Kubota E, Hata R
Organizer
Yokosuka Science Festa
Place of Presentation
Shonan Village Center, Hayama
Year and Date
20090000
-
-
-
-
-
-
-
-
-
-
-
